We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+56.43%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$172M
AUM Growth
–
Cap. Flow
+$143M
Cap. Flow %
83.09%
Top 10 Hldgs %
34.38%
Holding
84
New
84
Increased
–
Reduced
–
Closed
–
Avg Time Held Equity + Options
0 quarters
Top 10 Avg Time Held Equity + Options
0 quarters
Top 20 Avg Time Held Equity + Options
0 quarters
Avg Time Held Equity only
0 quarters
Top 10 Avg Time Held Equity only
0 quarters
Top 20 Avg Time Held Equity only
0 quarters

Top Buys

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$6.7M
2
INSM icon
Insmed
INSM
+$6.39M
3
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$5.26M
4
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$5.25M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$5.01M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 94.76%
2 Miscellaneous 4.88%
3 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
VCEL icon
1
Vericel Corp
VCEL
$2.06B
$8.69M 5.05%
+281,346
New +$6.7M
2020 Q4
0 quarters
BIIB icon
2
CALL
Biogen
BIIB
$33.8B
$7.35M 4.27%
+30,000
New +$7.74M
2020 Q4
0 quarters
ITCI icon
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.36M 3.7%
+200,000
New +$5.26M
2020 Q4
0 quarters
DCTH icon
4
Delcath Systems
DCTH
$532M
$6.3M 3.66%
+351,616
New +$4.82M
2020 Q4
0 quarters
INSM icon
5
Insmed
INSM
$21.1B
$5.83M 3.38%
+175,000
New +$6.39M
2020 Q4
0 quarters
AMYT
6
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$5.7M 3.31%
+402,556
New +$5.25M
2020 Q4
0 quarters
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.01M 2.91%
+227,388
New +$5.01M
2020 Q4
0 quarters
ARVN icon
8
Arvinas
ARVN
$447M
$4.67M 2.71%
+55,000
New +$1.9M
2020 Q4
0 quarters
LRMR icon
9
Larimar Therapeutics
LRMR
$224M
$4.65M 2.7%
+217,203
New +$4.35M
2020 Q4
0 quarters
IMVT icon
10
Immunovant
IMVT
$5.93B
$4.62M 2.68%
+100,000
New +$4.62M
2020 Q4
0 quarters
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.39M 2.55%
+20,000
New +$4.32M
2020 Q4
0 quarters
CRIS icon
12
Curis
CRIS
$1.49M
$4.34M 2.52%
+1,325
New +$1.59M
2020 Q4
0 quarters
HALO icon
13
Halozyme
HALO
$12.4B
$4.27M 2.48%
+100,000
New +$3.59M
2020 Q4
0 quarters
TCRR
14
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$4.21M 2.44%
+136,000
New +$3.44M
2020 Q4
0 quarters
STRO icon
15
Sutro Biopharma
STRO
$183M
$4.02M 2.33%
+18,500
New +$3.06M
2020 Q4
0 quarters
IMGN icon
16
DELISTED
Immunogen Inc
IMGN
$3.87M 2.25%
+600,000
New +$3.5M
2020 Q4
0 quarters
EPIX icon
17
DELISTED
ESSA Pharma
EPIX
$3.85M 2.24%
+322,917
New +$2.27M
2020 Q4
0 quarters
CLRB icon
18
Cellectar Biosciences
CLRB
$13.1M
$3.69M 2.14%
+5,909
New +$2.72M
2020 Q4
0 quarters
CCXI icon
19
DELISTED
ChemoCentryx, Inc.
CCXI
$3.33M 1.93%
+53,766
New +$3.08M
2020 Q4
0 quarters
KURA icon
20
Kura Oncology
KURA
$874M
$2.94M 1.71%
+90,000
New +$3.16M
2020 Q4
0 quarters
ASND icon
21
Ascendis Pharma A/S
ASND
$14.7B
$2.93M 1.7%
+17,556
New +$2.9M
2020 Q4
0 quarters
JNCE
22
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.85M 1.65%
+406,665
New +$3.17M
2020 Q4
0 quarters
EVGN icon
23
Evogene
EVGN
$6.17M
$2.82M 1.64%
+60,000
New +$2.12M
2020 Q4
0 quarters
COGT icon
24
Cogent Biosciences
COGT
$4.87B
$2.64M 1.53%
+235,066
New +$2.58M
2020 Q4
0 quarters
MLTX icon
25
MoonLake Immunotherapeutics
MLTX
$886M
$2.44M 1.42%
+215,071
New +$2.28M
2020 Q4
0 quarters
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Silverarc Capital Management, which disclosed 84 positions worth $172M. Its ten largest holdings account for 34% of the portfolio.

Its largest position is Vericel Corp: 281,346 shares worth $8.69M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, followed by Miscellaneous and Financials.

  • Silverarc Capital Management's largest Q4 2020 buy was Vericel Corp: 281,346 shares worth $8.69M.
  • Silverarc Capital Management's ten largest holdings make up 34% of its $172M portfolio in Q4 2020.
  • Silverarc Capital Management disclosed 84 positions in Q4 2020, its first 13F filing on record.

Based on Silverarc Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.